Lingotto Investment Management LLP Grows Position in Moderna, Inc. $MRNA

Lingotto Investment Management LLP raised its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 33.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 498,693 shares of the company’s stock after buying an additional 125,598 shares during the quarter. Moderna comprises about 0.3% of Lingotto Investment Management LLP’s portfolio, making the stock its 26th biggest holding. Lingotto Investment Management LLP’s holdings in Moderna were worth $14,706,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of MRNA. MUFG Securities EMEA plc acquired a new position in shares of Moderna during the 2nd quarter valued at about $28,000. Flagship Harbor Advisors LLC acquired a new position in shares of Moderna during the 4th quarter valued at about $31,000. Ameriflex Group Inc. boosted its position in shares of Moderna by 3,775.0% during the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after acquiring an additional 1,208 shares during the last quarter. Cromwell Holdings LLC boosted its position in shares of Moderna by 39.7% during the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after acquiring an additional 341 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Moderna by 148.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after acquiring an additional 801 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Trading Down 2.4%

NASDAQ MRNA opened at $46.06 on Tuesday. The firm’s 50-day moving average is $50.11 and its two-hundred day moving average is $42.66. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $59.55. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. The stock has a market capitalization of $18.28 billion, a P/E ratio of -5.65 and a beta of 1.05.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The company had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. During the same period in the previous year, the company earned ($2.52) EPS. The company’s quarterly revenue was up 260.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Moderna, Inc. will post -6.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Jefferies Financial Group set a $37.00 price target on shares of Moderna and gave the company a “hold” rating in a research report on Tuesday, March 3rd. Morgan Stanley set a $33.00 price target on shares of Moderna in a research report on Friday, May 1st. The Goldman Sachs Group boosted their price target on shares of Moderna from $43.00 to $49.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Piper Sandler boosted their price target on shares of Moderna from $63.00 to $69.00 and gave the company an “overweight” rating in a research report on Monday, February 23rd. Finally, Evercore set a $35.00 price target on shares of Moderna in a research report on Tuesday, February 17th. Two equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $35.73.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna announced an expanded collaboration with CEPI to support preclinical work and Phase 1 testing of a Bundibugyo ebolavirus vaccine candidate, with up to $50 million in external funding helping offset development costs. Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
• Positive Sentiment: Moderna and Merck reported 5-year follow-up data for intismeran autogene (V940), showing a 49% reduction in recurrence or death and a 59% reduction in distant metastasis or death versus KEYTRUDA alone in high-risk melanoma. Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA
• Neutral Sentiment: Several follow-on articles and transcripts reiterated the same Ebola and melanoma headlines, reinforcing investor attention but not adding materially new information. Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine
• Neutral Sentiment: Media coverage of personalized mRNA cancer vaccine research in melanoma also supported the broader mRNA platform narrative, but these reports were about the field more than a direct new Moderna catalyst. A cancer vaccine made just for you. mRNA is back and it’s fighting melanoma

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $48.40, for a total transaction of $2,581,462.40. Following the sale, the president directly owned 1,477,997 shares in the company, valued at $71,535,054.80. This represents a 3.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Abbas Hussain sold 5,682 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $46.63, for a total transaction of $264,951.66. Following the sale, the director owned 12,066 shares in the company, valued at $562,637.58. This trade represents a 32.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 68,281 shares of company stock valued at $3,280,293 over the last 90 days. 10.80% of the stock is owned by insiders.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.